Innovative Cancer Testing Global Cancer Diagnostics has developed a proprietary blood test specifically targeting early-stage lung cancer detection in high-risk populations, which presents an opportunity to expand partnerships with healthcare providers, clinics, and insurance companies seeking innovative screening solutions.

Affordable Pricing Model The company offers its Lung Cancer Test at an accessible price of $99, making it an attractive option for cost-conscious healthcare systems and patient populations, thereby facilitating market penetration and volume growth potential.

Market Entry Strategy Since the test was launched in October 2014 with minimal financial data indicating revenue under one million dollars, there is significant scope to increase sales through targeted outreach to clinics, hospitals, and health networks specializing in respiratory and cancer screenings.

Partnership Opportunities Given the company's niche focus and the sizable competitive landscape including firms like Guardant Health and Foundation Medicine, establishing strategic collaborations with larger biotech or healthcare companies could accelerate market adoption.

Growth and Expansion With a small team and emerging market presence, expanding sales efforts into national and international markets by leveraging partnerships and demonstrating clinical validation could substantially boost revenue and brand awareness within the oncology diagnostics space.